TrialDiabetes, obesity & metabolism2026

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.

Saichun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.